| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8540665 | POWDER PHARMS | Particle cassettes and processes therefor |
Oct, 2029
(6 years from now) | |
| US9358338 | POWDER PHARMS | Particle cassettes and processes therefor |
Apr, 2035
(11 years from now) | |
| US9370622 | POWDER PHARMS | Devices and methods for delivering particles |
Sep, 2035
(12 years from now) | |
Zingo is owned by Powder Pharms.
Zingo contains Lidocaine Hydrochloride.
Zingo has a total of 3 drug patents out of which 0 drug patents have expired.
Zingo was authorised for market use on 16 August, 2007.
Zingo is available in system;intradermal dosage forms.
Zingo can be used as zingo is a powder intradermal system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action, zingo intradermal injection system is a drug delivery system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action.
The generics of Zingo are possible to be released after 28 September, 2035.
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 August, 2007
Treatment: Zingo intradermal injection system is a drug delivery system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action; Zingo is a powder intrader...
Dosage: SYSTEM;INTRADERMAL
ZINGO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic